$1.15
4.17% today
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US15117K1034
Symbol
CLLS
Sector
Industry

Cellectis SA Sponsored ADR Stock price

$1.15
-0.11 8.73% 1M
-0.74 39.28% 6M
-0.65 36.11% YTD
-1.60 58.18% 1Y
-3.78 76.67% 3Y
-7.70 87.01% 5Y
-31.71 96.50% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.05 4.17%
ISIN
US15117K1034
Symbol
CLLS
Sector
Industry

Key metrics

Market capitalization $86.51m
Enterprise Value $-64.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -1.55
P/S ratio (TTM) P/S ratio 2.08
P/B ratio (TTM) P/B ratio 0.92
Revenue growth (TTM) Revenue growth 5,397.35%
Revenue (TTM) Revenue $41.51m
EBIT (operating result TTM) EBIT $-72.77m
Free Cash Flow (TTM) Free Cash Flow $19.56m
Cash position $260.31m
EPS (TTM) EPS $-0.37
P/E forward negative
P/S forward 1.63
EV/Sales forward negative
Short interest 0.27%
Show more

Is Cellectis SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Cellectis SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Cellectis SA Sponsored ADR forecast:

3x Buy
60%
2x Hold
40%

Analyst Opinions

5 Analysts have issued a Cellectis SA Sponsored ADR forecast:

Buy
60%
Hold
40%

Financial data from Cellectis SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
42 42
5,362% 5,362%
100%
- Direct Costs 20 20
3% 3%
48%
22 22
217% 217%
52%
- Selling and Administrative Expenses - -
- Research and Development Expense 85 85
3% 3%
205%
-53 -53
40% 40%
-127%
- Depreciation and Amortization 20 20
7% 7%
48%
EBIT (Operating Income) EBIT -73 -73
32% 32%
-175%
Net Profit -37 -37
64% 64%
-89%

In millions USD.

Don't miss a Thing! We will send you all news about Cellectis SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cellectis SA Sponsored ADR Stock News

Neutral
Seeking Alpha
21 days ago
Cellectis S.A. (NASDAQ:CLLS ) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO Conference Call Participants Gena Wang - Barclays Jack Allen - Baird Sebastiaan van der Schoot - Kempen Silvan Tuerkcan - Citizens Jack Allen - Baird Hangfei Fu - Jefferies Operator Good day, everyo...
Neutral
GlobeNewsWire
22 days ago
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL.
Neutral
GlobeNewsWire
28 days ago
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after t...
More Cellectis SA Sponsored ADR News

Company Profile

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Head office France
CEO André Choulika
Employees 222
Founded 1999
Website www.cellectis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today